share_log

Collegium Pharmaceutical Analyst Ratings

Collegium Pharmaceutical Analyst Ratings

Collegium 制药分析师评级
Benzinga ·  2023/08/25 02:58
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/25/2023 53.13% Needham $35 → $36 Maintains Buy
08/04/2023 — HC Wainwright & Co. Reiterates → Neutral
08/04/2023 48.87% Needham → $35 Reiterates Buy → Buy
05/30/2023 48.87% Needham → $35 Reiterates Buy → Buy
05/05/2023 48.87% Needham → $35 Reiterates → Buy
05/02/2023 27.61% Jefferies → $30 Assumes → Buy
04/19/2023 48.87% Needham → $35 Reiterates → Buy
02/24/2023 48.87% Needham → $35 Reiterates → Buy
02/08/2023 48.87% Needham → $35 Reiterates → Buy
01/05/2023 48.87% Needham $34 → $35 Maintains Buy
11/04/2022 44.62% Needham $36 → $34 Maintains Buy
08/08/2022 — HC Wainwright & Co. Downgrades Buy → Neutral
04/06/2022 53.13% Needham $34 → $36 Maintains Buy
02/22/2022 78.65% Piper Sandler $36 → $42 Maintains Overweight
02/15/2022 23.35% HC Wainwright & Co. $26 → $29 Maintains Buy
02/15/2022 44.62% Needham $28 → $34 Maintains Buy
11/15/2021 19.1% Needham $26 → $28 Maintains Buy
11/05/2021 10.59% Needham $32 → $26 Maintains Buy
08/06/2021 -6.42% Cantor Fitzgerald $30 → $22 Downgrades Overweight → Neutral
08/06/2021 36.11% Needham $34 → $32 Maintains Buy
08/06/2021 19.1% HC Wainwright & Co. $33 → $28 Maintains Buy
01/11/2021 40.37% HC Wainwright & Co. $29 → $33 Maintains Buy
11/09/2020 23.35% HC Wainwright & Co. $31 → $29 Maintains Buy
07/14/2020 -65.97% BWS Financial → $8 Initiates Coverage On → Sell
05/27/2020 — Guggenheim Initiates Coverage On → Neutral
05/08/2020 53.13% Needham $38 → $36 Maintains Buy
02/12/2020 48.87% Piper Sandler $27 → $35 Maintains Overweight
02/07/2020 27.61% Cantor Fitzgerald $24 → $30 Maintains Overweight
02/07/2020 61.63% Needham $36 → $38 Maintains Buy
01/08/2020 53.13% Needham $28 → $36 Maintains Hold
08/08/2019 2.08% Cantor Fitzgerald $35 → $24 Reiterates → Overweight
05/03/2019 -2.17% HC Wainwright & Co. → $23 Assumes → Buy
04/12/2019 — Janney Montgomery Scott Assumes → Buy
03/20/2019 -6.42% SunTrust Robinson Humphrey → $22 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
2023年08月25日 53.13% 李约瑟 $35→$36 维护 买
08/04/2023 - HC Wainwright公司 重申 →中性
08/04/2023 48.87% 李约瑟 →$35 重申 购买→购买
2023年05月30日 48.87% 李约瑟 →$35 重申 购买→购买
05/05/2023 48.87% 李约瑟 →$35 重申 →购买
05/02/2023 27.61% 杰富瑞 →$30 假设 →购买
04/19/2023 48.87% 李约瑟 →$35 重申 →购买
02/24/2023 48.87% 李约瑟 →$35 重申 →购买
02/08/2023 48.87% 李约瑟 →$35 重申 →购买
01/05/2023 48.87% 李约瑟 $34→$35 维护 买
11/04/2022 44.62% 李约瑟 $36→$34 维护 买
2022/08/08 - HC Wainwright公司 评级下调 购买→中性
04/06/2022 53.13% 李约瑟 $34→$36 维护 买
02/22/2022 78.65% 派珀·桑德勒 $36→$42 维护 超重
02/15/2022 23.35% HC Wainwright公司 $26→$29 维护 买
02/15/2022 44.62% 李约瑟 $28→$34 维护 买
2021年11月15日 19.1% 李约瑟 $26→$28 维护 买
2021年11月05日 10.59% 李约瑟 $32→$26 维护 买
08/06/2021 -6.42% 康托·菲茨杰拉德 $30→$22 评级下调 超重→中性
08/06/2021 36.11% 李约瑟 $34→$32 维护 买
08/06/2021 19.1% HC Wainwright公司 $33→$28 维护 买
2021/11/01 40.37% HC Wainwright公司 $29→$33 维护 买
11/09/2020 23.35% HC Wainwright公司 $31→$29 维护 买
07/14/2020 -65.97% BWS金融 →$8 开始承保 →销售
05/27/2020 - 古根海姆 开始承保 →中性
05/08/2020 53.13% 李约瑟 $38→$36 维护 买
02/12/2020 48.87% 派珀·桑德勒 $27→$35 维护 超重
02/07/2020 27.61% 康托·菲茨杰拉德 $24→$30 维护 超重
02/07/2020 61.63% 李约瑟 $36→$38 维护 买
1/08/2020 53.13% 李约瑟 $28→$36 维护 保持
2019年08月08日 2.08% 康托·菲茨杰拉德 $35→$24 重申 →超重
2019年05月03日 -2.17% HC Wainwright公司 →$23 假设 →购买
2019年4月12日 - 詹尼·蒙哥马利·斯科特 假设 →购买
2019/03/20 -6.42% SunTrust Robinson Humphrey →$22 开始承保 →购买

What is the target price for Collegium Pharmaceutical (COLL)?

科莱姆制药公司(Colcium Pharmtics)的目标价是多少？

The latest price target for Collegium Pharmaceutical (NASDAQ: COLL) was reported by Needham on August 25, 2023. The analyst firm set a price target for $36.00 expecting COLL to rise to within 12 months (a possible 53.13% upside). 11 analyst firms have reported ratings in the last year.

李约瑟于2023年8月25日报道了科尔制药(纳斯达克代码：COL)的最新目标价。这家分析公司将目标价定为36.00美元，预计Coll将在12个月内上涨(可能上涨53.13%)。过去一年，有11家分析公司公布了评级。

What is the most recent analyst rating for Collegium Pharmaceutical (COLL)?

科莱姆制药公司(Coll)最近的分析师评级是多少？

The latest analyst rating for Collegium Pharmaceutical (NASDAQ: COLL) was provided by Needham, and Collegium Pharmaceutical maintained their buy rating.

Needham提供了对科大药业(纳斯达克代码：COL)的最新分析师评级，科大药业维持其买入评级。

When is the next analyst rating going to be posted or updated for Collegium Pharmaceutical (COLL)?

科莱姆制药(Coll)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Collegium Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Collegium Pharmaceutical was filed on August 25, 2023 so you should expect the next rating to be made available sometime around August 25, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与科莱姆制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Colcium Pharmtics的上一次评级是在2023年8月25日提交的，所以你应该预计下一次评级将在2024年8月25日左右的某个时候公布。

Is the Analyst Rating Collegium Pharmaceutical (COLL) correct?

分析师对科尔制药(Colcium Pharmtics)的评级正确吗？

While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a maintained with a price target of $35.00 to $36.00. The current price Collegium Pharmaceutical (COLL) is trading at is $23.51, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的大学制药(COL)评级维持不变，目标价在35.00美元至36.00美元之间。科莱姆制药公司目前的股价为23.51美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发